Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. is actively expanding its overseas business and is involved in a significant asset restructuring transaction to acquire 100% equity of Weigao Puri Pharmaceutical Packaging Co., Ltd. [3] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [2][3] - The company was established on December 27, 2004, and was listed on May 19, 2025 [3][7] - The revenue composition of the company includes consumables (77.55%), equipment (18.25%), and other categories (4.20%) [7] Financial Performance - For the period from January to September 2025, the company achieved a revenue of 2.736 billion yuan, representing a year-on-year growth of 3.45% [7] - The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [7] - The company has distributed a total of 65.8213 million yuan in dividends since its A-share listing [8] Market Activity - On February 4, the stock price of Weigao Blood Purification increased by 0.17%, with a trading volume of 36.6268 million yuan and a turnover rate of 2.32%, resulting in a total market capitalization of 16.815 billion yuan [1] - The stock has seen a net outflow of 2.0387 million yuan from major investors today, with a continuous reduction in holdings over the past three days [4][5] Technical Analysis - The average trading cost of the stock is 41.25 yuan, with recent reductions in holdings slowing down [6] - The current stock price is fluctuating between a resistance level of 40.53 yuan and a support level of 39.80 yuan, indicating potential for range trading [6]
威高血净涨0.17%，成交额3662.68万元，后市是否有机会？